Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2010 1
2011 2
2012 1
2013 1
2015 2
2016 9
2017 16
2018 22
2019 23
2020 26
2021 27
2022 29
2023 33
2024 8

Text availability

Article attribute

Article type

Publication date

Search Results

175 results

Results by year

Filters applied: . Clear all
Page 1
Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRASG12C-Mutated NSCLC Treated With Sotorasib.
Ernst SM, van Marion R, Atmodimedjo PN, de Jonge E, Mathijssen RHJ, Paats MS, de Bruijn P, Koolen SL, von der Thüsen JH, Aerts JGJV, van Schaik RHN, Dubbink HJ, Dingemans AC. Ernst SM, et al. Among authors: dingemans ac. J Thorac Oncol. 2024 Apr 12:S1556-0864(24)00165-5. doi: 10.1016/j.jtho.2024.04.007. Online ahead of print. J Thorac Oncol. 2024. PMID: 38615940 Free article.
Osimertinib Plasma Trough Concentration in Relation to Brain Metastases Development in Patients With Advanced EGFR-Mutated NSCLC.
Gulikers JL, Veerman GDM, Jebbink M, Kruithof PD, Steendam CMJ, Boosman RJ, Mathijssen RHJ, Tjan-Heijnen VCG, Driessen JHM, Dursun S, Smit EF, Dingemans AC, van Geel RMJM, Croes S, Hendriks LEL. Gulikers JL, et al. Among authors: dingemans ac. JTO Clin Res Rep. 2024 Feb 20;5(4):100656. doi: 10.1016/j.jtocrr.2024.100656. eCollection 2024 Apr. JTO Clin Res Rep. 2024. PMID: 38550297 Free PMC article.
Hepatotoxicity in patients with non-small cell lung cancer treated with sotorasib after prior immunotherapy: a comprehensive clinical and pharmacokinetic analysis.
Ernst SM, Hofman MM, van der Horst TE, Paats MS, Heijboer FWJ, Aerts JGJV, Dumoulin DW, Cornelissen R, von der Thüsen JH, de Bruijn P, Hoop EO, Mathijssen RHJ, Koolen SLW, Dingemans AC. Ernst SM, et al. Among authors: dingemans ac. EBioMedicine. 2024 Apr;102:105074. doi: 10.1016/j.ebiom.2024.105074. Epub 2024 Mar 19. EBioMedicine. 2024. PMID: 38507877 Free PMC article.
Quantitative modeling of tumor dynamics and development of drug resistance in non-small cell lung cancer patients treated with erlotinib.
Yin A, Veerman GDM, van Hasselt JGC, Steendam CMJ, Dubbink HJ, Guchelaar HJ, Friberg LE, Dingemans AC, Mathijssen RHJ, Moes DJAR. Yin A, et al. Among authors: dingemans ac. CPT Pharmacometrics Syst Pharmacol. 2024 Apr;13(4):612-623. doi: 10.1002/psp4.13105. Epub 2024 Feb 20. CPT Pharmacometrics Syst Pharmacol. 2024. PMID: 38375997 Free PMC article.
Overall Survival From the EORTC LCG-1613 APPLE Trial of Osimertinib Versus Gefitinib Followed by Osimertinib in Advanced EGFR-Mutant Non-Small-Cell Lung Cancer.
Remon J, Besse B, Aix SP, Callejo A, Al-Rabi K, Bernabe R, Greillier L, Majem M, Reguart N, Monnet I, Cousin S, Garrido P, Robinet G, Campelo RG, Madroszyk A, Mazières J, Curcio H, Wasąg B, Pretzenbacher Y, Grillet F, Dingemans AC, Dziadziuszko R. Remon J, et al. Among authors: dingemans ac. J Clin Oncol. 2024 Apr 20;42(12):1350-1356. doi: 10.1200/JCO.23.01521. Epub 2024 Feb 7. J Clin Oncol. 2024. PMID: 38324744
Identification of protein biomarkers for prediction of response to platinum-based treatment regimens in patients with non-small cell lung cancer.
Böttger F, Radonic T, Bahce I, Monkhorst K, Piersma SR, Pham TV, Dingemans AC, Hillen LM, Santarpia M, Giovannetti E, Smit EF, Burgers SA, Jimenez CR. Böttger F, et al. Among authors: dingemans ac. Mol Oncol. 2023 Nov 27. doi: 10.1002/1878-0261.13555. Online ahead of print. Mol Oncol. 2023. PMID: 38010703 Free article.
175 results